Abstract: Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g., as liposomal delivery vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and subsequent transfection of said target cells, and in certain embodiments are characterized as having one or more properties that afford such compounds advantages relative to other similarly classified lipids.
Type:
Grant
Filed:
August 3, 2020
Date of Patent:
June 4, 2024
Assignee:
TRANSLATE BIO, INC.
Inventors:
Frank DeRosa, Braydon Charles Guild, Michael Heartlein
Abstract: The present invention provides, among other things, a method of intra-articular delivery of messenger RNA (mRNA), comprising administering into a joint of a subject in need of delivery a composition comprising an mRNA encoding a protein, such that the administering of the composition results in expression of the protein encoded by the mRNA in the joint.
Abstract: A system and a method that output in both a machine-readable and a human-readable format, a result obtained by performing a diagnosis of a disease through an image of living tissue. A diagnosis result generation system includes a marking information generation module for generating marking information indicating a result obtained by diagnosing whether a disease is present in biological tissue provided on a slide of which a biological image is obtained therefrom, wherein the marking information includes disease state information for each pixel of the biometric image obtained from the slide; a contour extraction module for extracting at least one contour from the marking information; and a machine-readable/human-readable generation module for generating a machine-readable/human-readable document including outline information of each of the at least one extracted contour.
Abstract: Methods and systems are provided for generating and utilizing a bacterial composition that comprises at least one genetically engineered bacterial strain that fixes atmospheric nitrogen in an agricultural system that has been fertilized with more than 20 lbs of Nitrogen per acre.
Type:
Grant
Filed:
October 23, 2018
Date of Patent:
May 28, 2024
Assignee:
Pivot Bio, Inc.
Inventors:
Alvin Tamsir, Sarah Bloch, Douglas Higgins
Abstract: Major histocompatibility complex-based chimeric receptors (MHC-CAR) for use in targeting autoreactive immune cells. Also provided herewith are genetically engineered immune cells expressing the MHC-CAR for use in treating autoimmune diseases such as multiple sclerosis.
Abstract: Disclosed is a nitrogen-containing heterocyclic compound, pharmaceutical compositions thereof and use thereof. The present disclosure provides a nitrogen-containing heterocyclic compound represented by formula I, a pharmaceutically acceptable salt thereof, a solvate thereof, a solvate of pharmaceutically acceptable salt thereof, a crystal thereof, a stereoisomer thereof, a tautomer thereof or an isotopically labeled compound thereof. The nitrogen-containing heterocyclic compound represented by formula I is expected to treat and/or prevent various PI3K-meditated diseases.
Type:
Application
Filed:
September 11, 2023
Publication date:
May 16, 2024
Applicant:
280 Bio, Inc.
Inventors:
Zusheng XU, Lin XIA, Xiangqian LI, Haoran YANG
Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for the treatment of retinal binding protein (RBP4) related diseases, such as obesity and the like.
Type:
Grant
Filed:
April 12, 2021
Date of Patent:
May 14, 2024
Assignees:
Belite Bio, Inc, The Trustees of Columbia University in the City of New York
Inventors:
Yu-Hsin Tom Lin, Cheng-Chi Irene Wang, Konstantin Petrukhin
Abstract: Described herein are methods and compositions for using microbial agents (probiotics) and agents that promote growth of certain microbes (prebiotics) for management (including prevention and treatment) of musculoskeletal disorders, including osteoporosis, osteopenia, Paget's disease, stunting, osteoarthritis, osteomyelitis, and delayed or non-union fractures. Also described herein are methods and compositions for using probiotics and prebiotics for management of inflammation, and symptoms of menopause.
Type:
Grant
Filed:
November 7, 2022
Date of Patent:
May 14, 2024
Assignee:
SOLAREA BIO, INC.
Inventors:
Eric Michael Schott, Gerardo V. Toledo, Maria Juliana Soto-Giron
Abstract: The present invention relates, in part, to methods for large-scale purification of mRNA. The method includes, at least, steps of forming an mRNA slurry, stirring the slurry, and vacuum or pressure filtering the slurry.
Type:
Grant
Filed:
October 14, 2020
Date of Patent:
May 7, 2024
Assignee:
TRANSLATE BIO, INC.
Inventors:
Jonathan Abysalh, Daniel Crawford, Frank DeRosa, Shrirang Karve, Anusha Dias, Michael Heartlein
Abstract: The invention provides improved compositions for adoptive cell therapies for cancers. The invention generally provides improved vectors for generating T cell therapies and methods of using the same. More particularly, the invention provides salvage CARs, dimerizable salvage receptors, and their use in treating, preventing, or ameliorating cancers, and in particular preferred embodiments relapsed or refractory cancer. In various embodiments, a salvage chimeric antigen receptor (CAR) is provided comprising: an extracellular antigen binding domain; a multimerization domain; a transmembrane domain; one or more intracellular co-stimulatory signaling domains; and/or a primary signaling domain.
Abstract: Disclosed are cationic polymers comprising monomers such as those described in Formula (I). Such polymers can be useful for the preparation of therapeutic compositions [e.g., compositions comprising nucleic acids such as m RNA). Additionally, therapeutic compositions comprising these cationic, biodegradable polymers can have improved properties and reduced toxicity.
Type:
Grant
Filed:
February 1, 2019
Date of Patent:
May 7, 2024
Assignee:
TRANSLATE BIO, INC.
Inventors:
Frank DeRosa, Michael Heartlein, Shrirang Karve, Zarna Patel
Abstract: This invention relates to methods and compositions useful for treatment of subjects with dry age-related macular degeneration or geographic atrophy secondary to dry age-related macular degeneration. The methods involve administration of a pharmaceutical composition comprising an anti-C5 agent ARC1905, which comprises a C5-specific aptamer conjugated to a polyethylene glycol moiety via a linker, in an amount effective for slowing or inhibiting loss of low luminance visual acuity in the subject. The aptamer consists of the sequence fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGfUfCfUmGmAmGfUfUfUAfCf CfUmGfCmG-3T, wherein fC and fU=2? fluoro nucleotides, mG and mA=2?-OMe nucleotides, all other nucleotides are 2?-OH, and 3T indicates an inverted deoxythymidine. Dosages and administration schedules are disclosed.
Abstract: Disclosed herein are non-naturally occurring vesicle comprising a chimeric vesicle localization moiety comprising a surface-and-transmembrane domain of a first vesicle localization moiety and a cytosolic domain of a second vesicle localization moiety, the method of making said vesicle and uses thereof.
Abstract: The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing a suspension of preformed lipid nanoparticles and mRNA.
Type:
Grant
Filed:
February 25, 2021
Date of Patent:
April 30, 2024
Assignee:
TRANSLATE BIO, INC.
Inventors:
Shrirang Karve, Ashish Sarode, Frank DeRosa
Abstract: This disclosure is drawn to substituted pyridine compounds and compositions, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing a neurological diseases.
Type:
Grant
Filed:
October 4, 2023
Date of Patent:
April 30, 2024
Assignee:
NURA BIO, INC.
Inventors:
Jennifer Aiden Kozak, Sean Pomeroy Brown, Christopher Michael Tegley, Alexander Wayne Schammel, Liusheng Zhu, Maximiliano De La Higuera Macias, Shilpa Sambashivan
Abstract: Provided herein are systems and methods for screening desirable biological variants using a high-throughput integrated system. The integrated system may be configured to input a plurality of parameters from functional studies of biological variants under applied conditions, in conjunction with integrated libraries of biological variants, and filter the inputs to produce desirable biological variants based on an input performance requirement. The system may output optimized strains, molecules, or novel molecules expected to have a desirable functional characteristic. Accordingly, the methods and systems disclosed herein enable multi-parametric studies of biological diversity and conditional diversity in systems biology.
Type:
Grant
Filed:
December 20, 2022
Date of Patent:
April 30, 2024
Assignee:
TRIPLEBAR BIO, INC.
Inventors:
Jeremy Agresti, Andres Ornelas Vargas, Kevin Gregory Hoff
Abstract: The present invention describes a second-generation tetanus toxoid vaccine and a process for the preparation thereof, comprising the steps of: inducing an E. Coli culture OD 600=0.5 by adding 0.2 mM IPTG; growing the culture at 14-16° C. for 14 to 20 hours; suspending the culture in 25 mM phosphate buffer containing 200 mM sodium chloride; adding 1% of triton-X-100 to the phosphate buffer, and adding the buffer to the culture; sonicating the culture for a period of 3 minutes (at 5 sec on/off pulse) at 4° C. on cold beads; centrifuging the culture for 60 to 90 minutes; collecting and purifying a supernatant using Ni-NTA affinity column with an eluant; and combining the supernatant into a pool with contaminated bands and concentrating using Centriprep-30 centrifuge filters (30 kDa pores).
Abstract: Disclosed are cationic lipids which are compounds of Formula (I?). Cationic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.
Type:
Grant
Filed:
May 15, 2019
Date of Patent:
April 23, 2024
Assignee:
TRANSLATE BIO, INC.
Inventors:
Frank DeRosa, Shrirang Karve, Yi Zhang, Michael Heartlein